

FMO-based Intermolecular Interaction Energy Analysis between SARS-CoV-2 Spike Protein and Its Drug Candidate Molecules

Chiduru Watanabe^{1,2}
chiduru.watanabe@riken.jp

Yoshio Okiyama³
okiyama@nihs.go.jp

Shigenori Tanaka⁴
tanaka2@kobe-u.ac.jp

Kaori Fukuzawa⁵
k-fukuzawa@hoshi.ac.jp

Teruki Honma¹
honma.teruki@riken.jp

¹ RIKEN Center for Biosystems Dynamics Research 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan

² JST, PRESTO, 4-1-8 Honcho, Kawaguchi, Saitama, 332-0012, Japan

³ National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki City, Kanagawa, 210-9501, Japan

⁴ Graduate School of System Informatics, Kobe University, 1-1 Rokkodai, Nada-ku, Kobe 657-8501, Japan

⁵ School of Pharmacy and Pharmaceutical Sciences, Hoshi University, 2-4-41 Ebara, Shinagawa-Ku, Tokyo, 142-8501, Japan

Keywords: SARS-CoV-2, PPI, antibody, FMO DB

Due to the COVID-19 pandemic, researchers have attempted to identify complex structures of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (S-protein) with angiotensin-converting enzyme 2 (ACE2), a blocking antibody, or a drug candidate molecule. We have performed fragment molecular orbital (FMO) calculations on the complexes of S-protein with ACE2 and antibodies to reveal key residues for molecular recognition mechanism [1]. To quantitatively evaluate hydrogen bonds, XH/ π interactions (X = N, O, and C), and salt bridges, we performed FMO-based epitope analysis with inter-fragment interaction energy (IFIE) and its energy decomposition analysis (PIEDA). In addition, molecular recognition between S-protein and another drug candidate molecule will be also reported by IFIE/PIEDA analysis. These FMO calculation data will be registered in FMO DB (<https://drugdesign.riken.jp/FMO DB/>).




Fig. 1. PIEDA between S-protein and ACE2

Acknowledgement

The authors thank Mr. Kazuki Watanabe for fruitful discussion, and Dr. Kikuko Kamisaka and Dr. Daisuke Takaya for technical support. This research was done in activities of FMO Drug Design Consortium (<https://fmodd.jp/top-en/>). The results of FMO calculations were partially obtained using the Fugaku supercomputer (project ID: 210130) and the HOKUSAI supercomputer (RIKEN Advanced Center for Computing and Communications, Saitama, Japan). This research was partially supported by Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED under Grant Number JP21am0101113. Finally, CW acknowledges JST PRESTO grant (JPMJPR18GD).

[1] Watanabe C *et al.*, Molecular recognition of SARS-CoV-2 spike glycoprotein: quantum chemical hot spot and epitope analyses, *Chem. Sci.*, 12, 4722-4739, 2021.